SCHEMBL3578009

SCHEMBL3578009

CN1CCN(c2ccc(NC=C3C(=O)NC(=O)c4ccc(-c5ccccc5F)cc43)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
WEE1 P30291 1/20 0.40
MAP4K1 Q92918 1/20 0.40
ALK Q9UM73 2/20 0.39
TNK2 Q07912 1/20 0.39
RPS6KA3 P51812 3/20 0.39
CSF1R P07333 2/20 0.38
WDR5 P61964 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PTPRC P08575 1/20 0.36
PTPN1 P18031 1/20 0.36
ERBB2 P04626 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3578006 1.00 NPC1 (0.42) NPC1RAB9AOPRM1OPRD1WEE1
SCHEMBL3569067 0.90 CSF1R (0.41) NPC1RAB9AMAP4K1TNK2CSF1R
SCHEMBL3569072 0.90 CSF1R (0.41) NPC1RAB9AMAP4K1TNK2CSF1R
SCHEMBL3575657 0.89 USP2 (0.39) RAB9AWEE1ALKTNK2CSF1R
SCHEMBL3575654 0.89 USP2 (0.39) RAB9AWEE1ALKTNK2CSF1R
SCHEMBL3573755 0.89 MAP4K1 (0.43) NPC1RAB9AMAP4K1ALKTNK2
SCHEMBL3574786 0.89 MAP4K1 (0.43) NPC1RAB9AMAP4K1ALKTNK2
SCHEMBL3573753 0.89 MAP4K1 (0.43) NPC1RAB9AMAP4K1ALKTNK2
SCHEMBL3574781 0.89 MAP4K1 (0.43) NPC1RAB9AMAP4K1ALKTNK2
SCHEMBL3574823 0.88 MAPKAPK2 (0.44) NPC1RAB9AALKRPS6KA3CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US claimed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 NPC1 538/4885RAB9A 1293/4885OPRM1 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.